Comparison 3. 5‐FU/cisplatin/anthracycline combinations versus 5‐FU/cisplatin combinations (without anthracyclines).
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 Overall survival | 4 | 579 | Hazard ratio (Fixed, 95% CI) | 0.74 [0.61, 0.89] |
2 Tumour response | 1 | Odds Ratio (M‐H, Fixed, 95% CI) | Subtotals only | |
3 Time to progression | 1 | Hazard Ratio (Fixed, 95% CI) | Subtotals only |